HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemoprevention of primary liver cancer: a randomized, double-blind trial in Linxian, China.

AbstractBACKGROUND:
Primary liver cancer is a common malignancy with a dismal prognosis. New primary prevention strategies are needed to reduce mortality from this disease. We examined the effects of supplementation with four different combinations of vitamins and minerals on primary liver cancer mortality among 29450 initially healthy adults from Linxian, China.
METHODS:
Participants were randomly assigned to take either a vitamin-mineral combination ("factor") or a placebo daily for 5.25 years (March 1986-May 1991). Four factors (at doses one to two times the US Recommended Daily Allowance)-retinol and zinc (factor A); riboflavin and niacin (factor B); ascorbic acid and molybdenum (factor C); and beta-carotene, alpha-tocopherol, and selenium (factor D)-were tested in a partial factorial design. The study outcome was primary liver cancer death occurring from 1986 through 2001. Adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of liver cancer death with and without each factor. All P values are two-sided.
RESULTS:
A total of 151 liver cancer deaths occurred during the analysis period. No statistically significant differences in liver cancer mortality were found comparing the presence and absence of any of the four intervention factors. However, both factor A and factor B reduced liver cancer mortality in individuals younger than 55 years at randomization (HR = 0.59, 95% CI = 0.34 to 1.00, and HR = 0.54, 95% CI = 0.31 to 0.93, respectively) but not in older individuals (HR = 1.06, 95% CI = 0.71 to 1.59, and HR = 1.12, 95% CI = 0.75 to 1.68, respectively). Factor C reduced liver cancer death, albeit with only borderline statistical significance in males (HR = 0.70, 95% CI = 0.47 to 1.02) but not in females (HR = 1.30, 95% CI = 0.72 to 2.37). Cumulative risks of liver cancer death were 6.0 per 1000 in the placebo arm, 5.4 per 1000 in the arms with two factors, and 2.4 per 1000 in the arm with all four factors.
CONCLUSION:
None of the factors tested reduced overall liver cancer mortality. However, three factors reduced liver cancer mortality in certain subgroups.
AuthorsChen-Xu Qu, Farin Kamangar, Jin-Hu Fan, Binbing Yu, Xiu-Di Sun, Philip R Taylor, Bingshu E Chen, Christian C Abnet, You-Lin Qiao, Steven D Mark, Sanford M Dawsey
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 99 Issue 16 Pg. 1240-7 (Aug 15 2007) ISSN: 1460-2105 [Electronic] United States
PMID17686823 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
Chemical References
  • Antibodies, Neoplasm
  • Minerals
  • Vitamins
Topics
  • Adult
  • Antibodies, Neoplasm (blood)
  • Chemoprevention
  • China
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Humans
  • Incidence
  • Liver Neoplasms (mortality, prevention & control)
  • Male
  • Middle Aged
  • Minerals (therapeutic use)
  • Vitamins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: